Loading, please wait...
• Describe the risks of comorbid psychiatric and medical comorbidities in people with Attention-deficit/hyperactivity disorder (ADHD)
• Explain the risks and prevention of medication diversion and misuse in people with ADHD
• Design an individualized management plan for people with ADHD
The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This online activity is approved for 0.10 CEUs (1.00 contact hour) of continuing education credit. To receive 1.00 contact hour of CE credit, the participant must watch the included video in its entirety, pass the online post-test ( >70% within 5 attempts), and complete the online evaluation. Upon successfully completing the course evaluation, the continuing pharmacy education credits will automatically be uploaded to CPE Monitor (allow 3-7 days).| Mental Health Awareness: ADHD Treatment Update |
About the Speaker
Stephen R. Saklad, Pharm.D., BCPP
Director, Psychiatric Pharmacy Program
Pharmacotherapy Education and Research Center
UT Health Science Center San Antonio
Dr. Saklad is a Clinical Professor at The University of Texas College of Pharmacy and a Pharmacist at San Antonio State Hospital since 1979. He has focused his career on clinical care, teaching, and research to improve the quality of life and function in the serious and persistently mentally ill. He helped to create a clinical research unit at San Antonio State Hospital and developed the first websites for The University of Texas College of Pharmacy and the College of Psychiatric and Neurologic Pharmacists (CPNP). He is the Director of the University of Texas Psychiatric Pharmacy Program in San Antonio, having trained over 70 advanced practice pharmacists in psychiatric pharmacy. Dr. Saklad is a Founding Member of CPNP, served on the CPNP Board of Directors and was the founding senior editor of their peer-reviewed journal, the Mental Health Clinician. He has published articles and presented to many groups around the country on a variety of pharmacy and mental health-related topics. He is a principal or co-investigator for several studies of the efficacy and adverse effects of Phase II, III, and IV psychotropic agents in schizophrenia, mood disorders, and other serious mental illnesses, as well as their pharmacokinetics and interactions. He has received several honors, most recently the Judith J. Saklad Memorial Award from CPNP in 2012 and the Teaching Excellence Award from the UT College of Pharmacy in 2013.
Disclosure: Dr. Stephen Saklad has the following relevant financial relationships, potential or perceived, with commercial or conflicts of interest to disclose:
Speakers Bureau: Actavis, Otsuka, Sunovion
Consultant: Janssen, Jazz, Otuska, Teva
Other: Member of Pharmacists Foundation, Business Development Council for San Antonio